Core Viewpoint - The article emphasizes the practical utility and value of the "Private Equity Investment Handbook," which covers essential aspects of private equity investment, including due diligence, risk management, investment agreements, and dispute resolution [1][3]. Summary by Sections Chapter 1: Due Diligence - The first chapter introduces the main processes and methods of due diligence in equity investment, focusing on the "Four Cores" of business due diligence, "Five Definitions" of financial due diligence, and "Six Dimensions" of legal due diligence [7]. - It details the "Four Cores" of business due diligence, which include business and product, target company's industry segmentation, R&D capabilities, and core competitiveness [7]. - The chapter also provides practical examples, such as the "Seven Axes" used by Muddy Waters for due diligence, which includes document review, related party checks, field research, and supplier investigations [10]. Chapter 2: Risk Management - The second chapter outlines three common business risks, four financial risks, ten legal risks, and valuation risks, along with risk mitigation strategies [10]. - It includes numerous case studies to illustrate practical applications, particularly focusing on the coherence of business logic through four specific cases [10][11]. - The chapter addresses shareholder verification issues, highlighting three practical problems encountered during IPO processes [13]. Chapter 3: Investment Agreements - The third chapter discusses the types and functions of investment agreements, detailing nearly 30 key clauses across eight categories [16]. - It emphasizes the importance of valuation adjustment clauses, which can help manage issues arising from short-term order pursuits that may harm long-term interests [16]. - Other critical clauses include anti-dilution clauses, mandatory sale rights, co-sale rights, priority liquidation rights, and restrictions on equity transfer [18]. Chapter 4: Betting Clauses - The fourth chapter elaborates on betting clauses, covering six dimensions such as betting subjects, conditions, repurchase timelines, and methods [20]. - It raises questions about the legal effectiveness of repurchase claims made by investors within the stipulated timeframe after betting conditions are triggered [20]. - The chapter discusses whether betting agreements must be declared before an IPO and outlines specific regulatory requirements [22]. Chapter 5: Disputes in Betting and Repurchase - The fifth chapter focuses on seven types of disputes related to betting and repurchase, analyzing numerous cases to interpret current judicial reasoning [23]. - It examines how courts adjudicate cases where both cash compensation and equity repurchase are requested by the target company [25]. - The chapter provides a systematic comparison of disputes in betting and repurchase from both practical and theoretical perspectives, making it engaging for readers [26].

近期，国家网信办会同金融管理部门依法处置一批散布资本市场不实信息、开展非法荐股、炒作虚拟货 币交易等的账号、网站。现将部分典型案例通报如下："爱股票APP"等账号发布资本市场不实信 息；"侃哥说财经"等账号开展非法荐股；"火哥聊加密"等账号、网站宣传炒作虚拟货币交易；"小北 呦"等账号散布金融领域黑灰产信息。 要闻速递 【国常会审议通过《制造业绿色低碳发展行动方案（2025—2027年）》】 近日召开的国常会审议通过《制造业绿色低碳发展行动方案（2025—2027年）》。会议指出，推进制造 业绿色低碳发展是大势所趋，要加快绿色科技创新和先进绿色技术推广应用，强化新型工业化绿色底 色。要推进传统产业深度绿色转型，结合大规模设备更新等政策实施，积极应用先进装备和工艺，加快 重点行业绿色改造升级。要引领新兴产业高起点绿色发展，加大清洁能源、绿色产品推广，提升资源循 环利用水平。 【国家网信办持续深入整治网上金融信息乱象】 【特朗普：6月1日起对欧盟征收50%关税对不在美国生产的手机制造商征收25%关税】 据央视新闻，美国总统特朗普表示，欧盟设置了强大的贸易壁垒、征收增值税、企业罚款、非货币贸易 壁垒、货币操纵、针对 ...

①MSCI中国指数调整将生效；②5月PMI数据将公布；③华为将举行尊界S800发布会。 除MSCI中国指数以外，MSCI中国A股在岸指数的成分股名单也有所调整，增加成分股8只，包括翱捷科技-U、中国卫通、海思科、杭钢股份、艾力斯、百 利天恒、拓维信息、芯原股份。调整结果将于5月30日收盘后生效。 5月PMI数据将公布 5月31日，国家统计局将公布5月PMI数据。据国家统计局，4月份，制造业采购经理指数为49.0%，比上月下降1.5个百分点；非制造业商务活动指数和综合 PMI产出指数分别为50.4%和50.2%，继续保持在扩张区间。 国家统计局服务业调查中心高级统计师赵庆河指出，总体看，综合PMI产出指数自2023年1月以来始终位于临界点以上，我国经济总体产出持续扩张，长期 向好的基本面没有改变。受外部环境急剧变化等因素影响，4月份制造业采购经理指数有所回落，但高技术制造业等相关行业继续保持扩张，以内销为主的 制造业企业生产经营总体稳定。 【重磅新闻】 MSCI中国指数调整将生效 日前，明晟公司（MSCI）公布了5月份指数审议结果。在本次调整中，MSCI中国指数新纳入芯原股份、百利天恒、惠泰医疗、光线传媒、海思 ...

Group 1: Market Performance - A number of leading stocks reached historical highs, including well-known industry leaders such as BYD, CITIC Bank, and Xinlitai, as well as niche market leaders like Hengxin Life, which saw a 20% limit-up increase [1] - BYD's stock rose by 4.22%, driving strength in the automotive supply chain, with seven out of the top ten stocks by trading volume belonging to the automotive sector [1] - The Shanghai Composite Index increased by 0.08%, the Shenzhen Component Index rose by 0.5%, and the ChiNext Index gained 0.48% [1] Group 2: Pharmaceutical Sector - The pharmaceutical sector showed strong performance, with significant gains in chemical pharmaceuticals, CRO, medical services, and innovative drugs [5] - Heng Rui Pharmaceutical's listing on the Hong Kong stock market saw a 30.87% increase, boosting sentiment in the pharmaceutical sector [8] - Multiple significant drugs received approval for market entry, including the innovative drug Anglazavir from Guangdong Zhongsheng Pharmaceutical, which led to a limit-up for the company [9]

Policy Developments - The total amount of personal accounts for employee medical insurance mutual aid reached 17.792 billion yuan from January to April 2025, with 133 million participants [2] Drug and Device Approvals - The KRAS G12C inhibitor, Gozai Lese, developed by Jako and Ailis, has been approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have previously received at least one line of systemic therapy [3] - Heng Rui Medicine's innovative drug, Regaglitin Metformin Tablets, has been approved for use in adults with type 2 diabetes to improve blood sugar control [4] Capital Markets - Boyin Hearing announced a B-round financing of several tens of millions, aimed at increasing investment in domestic hearing aid research and development [5] - Lid Health Technology has completed nearly 100 million yuan in angel round financing, with funds allocated for accelerating technology research and product commercialization [6] Major Industry Events - Rongchang Bio plans to place 19 million new H-shares at a price of 42.44 HKD per share, raising approximately 796 million HKD for core product pipeline expansion [7] - Haoyuan Pharmaceutical announced that its shareholder, Zhenjin Investment, has reduced its holdings by approximately 3.2 million shares, accounting for 1.51% of the total share capital [8] - Baiyatai has decided to terminate the BAT3306-002 study, which evaluated the pharmacokinetics, efficacy, and safety of BAT3306 in combination with chemotherapy in IV-stage NSCLC patients, after an investment of 224 million yuan in the project [9]

Core Viewpoint - The article discusses the approval of the KRAS G12C inhibitor, Goratirsen (brand name "Airikai"), by the National Medical Products Administration for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring the KRAS G12C mutation who have received at least one systemic therapy [2][3]. Group 1: Product Approval and Financial Implications - The approval of Goratirsen triggers a milestone payment of 50 million yuan to the developer, Gako Pharmaceutical, from its partner, Ailis [3]. - Lung cancer is the most prevalent and deadly malignancy globally, with non-small cell lung cancer accounting for approximately 85% of all lung cancer cases [3]. Group 2: Clinical Study Results - The approval is based on a pivotal Phase II single-arm study assessing the safety, tolerability, and efficacy of Goratirsen in patients with advanced NSCLC who have failed or are intolerant to standard treatments [3][4]. - The study included 119 NSCLC patients, with an independent review showing a confirmed objective response rate (cORR) of 49.6% (range: 40.2%-59.0%) and a disease control rate (DCR) of 86.3% (range: 78.7%-92.0%) [4]. - The median duration of response (DOR) was 14.5 months (range: 9.6-NE), median progression-free survival (PFS) was 8.2 months (range: 5.2-11.1), and median overall survival (OS) was 17.5 months (range: 13.6-NE) [4]. Group 3: Product Features and Future Developments - Goratirsen is the only KRAS G12C inhibitor approved in China that allows for once-daily oral administration, enhancing patient convenience [4]. - Ailis plans to commercialize Goratirsen and is conducting clinical studies for its use in combination with SHP2 inhibitors for first-line treatment of NSCLC, as well as for monotherapy in multiple tumor types [4].

Core Viewpoint - Shanghai Ailis Pharmaceutical Technology Co., Ltd. has announced a cash dividend distribution of RMB 0.40 per share (before tax), totaling RMB 180 million (before tax) for its shareholders, following the approval at the annual general meeting held on May 14, 2025 [1][5]. Dividend Distribution Plan - The dividend distribution is based on a total share capital of 450 million shares, with a cash dividend of RMB 0.40 per share, amounting to a total cash distribution of RMB 180 million (before tax) [1]. - The cash dividend will be distributed to all shareholders registered with China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the record date [1]. Relevant Dates - The key dates for the dividend distribution are as follows: - Record date - Ex-dividend date - Cash dividend payment date [1]. Taxation on Dividends - For individual shareholders holding unrestricted circulating shares: - Those holding shares for over 1 year will not be subject to personal income tax on dividend income, receiving a net cash dividend of RMB 0.40 per share [2]. - For shares held for 1 year or less, the company will not withhold personal income tax at the time of distribution; tax will be calculated upon the transfer of shares [2]. - The actual tax burden for shareholders varies based on the holding period: - Less than or equal to 1 month: 20% tax rate, effective cash dividend of RMB 0.32 per share - More than 1 month to 1 year: 10% tax rate, effective cash dividend of RMB 0.36 per share - Over 1 year: no tax [3][4]. Distribution to Foreign Investors - Qualified Foreign Institutional Investors (QFII) will have a withholding tax of 10%, resulting in an effective cash dividend of RMB 0.36 per share [4]. - For Hong Kong market investors, the same 10% withholding tax applies, with dividends distributed in RMB [4]. Contact Information - For inquiries regarding the dividend distribution, shareholders can contact the Securities Affairs Department at 021-80423292 [4].

Group 1 - Company Zhongnan Media signed a government procurement contract worth 1.009 billion yuan for the supply of free textbooks and related teaching resources in Hunan Province for 2025, ensuring stable revenue for the company [1] - Company Zhongnan Media was established in December 2008, focusing on the publishing, distribution, and printing of publications [2] Group 2 - Company Tongling Nonferrous Metals announced the resignation of its general manager and deputy general manager due to higher-level assignments [3] - Company Tongling Nonferrous Metals was founded in November 1996, primarily engaged in the mining and processing of copper, iron, and sulfur gold [4] Group 3 - Company Xinyi Co. plans to reduce its shareholding by no more than 1% due to personal asset allocation needs [5] - Company Xinyi Co. was established in April 1996, specializing in the research, production, and sales of functional new materials based on organic synthetic resins [6] Group 4 - Company Xinhua Pharmaceutical received approval for the registration of ibuprofen suspension drops, a non-prescription drug for relieving fever and mild to moderate pain in children [7] - Company Xinhua Pharmaceutical was founded in November 1998, focusing on the sales of raw materials and intermediates, as well as chemical products [8] Group 5 - Company Emei Mountain A elected Tong Jianming as a director and appointed him as the general manager [9] - Company Emei Mountain A was established in October 1997, primarily engaged in tourism services, including ticket sales and hotel operations [10] Group 6 - Company Heng Rui Medicine announced the approval of its innovative drug, Regaglitin Metformin tablets, for market launch, aimed at improving blood sugar control in type 2 diabetes patients [11] - Company Heng Rui Medicine was founded in April 1997, focusing on the research, production, and sales of pharmaceuticals [12] Group 7 - Company Chongqing Rural Commercial Bank announced the approval of Tang Li's qualification as vice president [13] - Company Chongqing Rural Commercial Bank was established in June 2008, focusing on inclusive finance and corporate financial services [14] Group 8 - Company Weili Medical received certification from the Canadian Ministry of Health for its extraction bag, allowing legal sales in the Canadian market [15] - Company Weili Medical was founded in April 2004, specializing in the research, production, and sales of medical devices in various fields [16] Group 9 - Company Ailis received approval for its KRAS G12C inhibitor, a new drug for treating advanced non-small cell lung cancer [17] - Company Ailis was established in March 2004, focusing on innovative drug research and development in oncology [18] Group 10 - Company Renfu Pharmaceutical received registration certificates for two new drugs, including methylprednisolone tablets and hydrocodone ibuprofen tablets [19] - Company Renfu Pharmaceutical was founded in March 1993, focusing on the research, production, and sales of pharmaceuticals [20] Group 11 - Company Siwei Tuxin received multiple invention patent certificates from the National Intellectual Property Administration [21] - Company Siwei Tuxin was established in December 2002, focusing on navigation maps, intelligent driving, and automotive electronic chips [22] Group 12 - Company Changhong High-Tech received a warning letter from the Ningbo Securities Regulatory Bureau for failing to disclose related party transactions [23] - Company Changhong High-Tech was founded in June 2012, focusing on the research, production, and sales of styrene thermoplastic elastomers [24] Group 13 - Company Gansu Energy Chemical announced the resignation of its director and general counsel due to organizational adjustments [25] - Company Gansu Energy Chemical was established in December 1996, focusing on coal mining and sales [26] Group 14 - Company Shanghai Construction received land use rights for a residential project in Tianjin, with a total investment of approximately 330 million yuan [27] - Company Shanghai Construction was founded in June 1998, focusing on construction, design consulting, and real estate development [28] Group 15 - Company Chengdu Xian Dao announced that a major shareholder plans to increase its stake in the company by 25 to 50 million yuan [29] - Company Chengdu Xian Dao was established in February 2012, focusing on drug research and development services [30] Group 16 - Company Hunan Silver announced the resignation of its deputy general manager due to organizational adjustments [31] - Company Hunan Silver was founded in November 2004, focusing on the smelting and sales of silver and other precious metals [32] Group 17 - Company China Chemical reported a total contract amount of 123.017 billion yuan for the first four months of the year [33] - Company China Chemical was established in September 2008, focusing on construction engineering and modern services [34] Group 18 - Company Borui Pharmaceutical received a registration certificate for iodinated contrast agent injection [35] - Company Borui Pharmaceutical was founded in October 2001, focusing on the research and production of pharmaceutical intermediates and raw materials [36] Group 19 - Company Wanhua Chemical announced a technical transformation of its ethylene unit, aiming to diversify raw materials and enhance competitiveness [37] - Company Wanhua Chemical was established in December 1998, focusing on the research, production, and sales of polyurethane and fine chemicals [38] Group 20 - Company ST Houlv received approval for its injectable cephalosporin sodium to pass the consistency evaluation for generic drugs [39] - Company ST Houlv was founded in June 2005, focusing on drug research, production, and sales [40] Group 21 - Company Anka Intelligent announced a targeted reduction of capital for its subsidiary [41] - Company Anka Intelligent was established in May 2004, focusing on the research and development of power system solutions [42] Group 22 - Company Huaming Intelligent announced financial support for its subsidiary [43] - Company Huaming Intelligent was founded in August 2001, focusing on intelligent systems and services [44] Group 23 - Company Foton Motor received a central subsidy of 124 million yuan for promoting new energy vehicles [45] - Company Foton Motor was established in August 1996, focusing on vehicles and mobile equipment [46] Group 24 - Company Guangsheng Tang received a registration certificate for ritonavir tablets, used in HIV treatment [47] - Company Guangsheng Tang was founded in June 2001, focusing on the research and production of antiviral drugs [48] Group 25 - Company Kexing Pharmaceutical received FDA approval for clinical trials of its GB18 injection in the United States [49] - Company Kexing Pharmaceutical was established in August 1997, focusing on the research and production of recombinant protein drugs [50] Group 26 - Company Heng Rui Medicine announced the final price for its H-share public offering at 44.05 HKD per share [51] - Company Heng Rui Medicine was founded in April 1997, focusing on the research, production, and sales of pharmaceuticals [52] Group 27 - Company Wandong Medical elected a new chairman following the resignation of the previous chairman [53] - Company Wandong Medical was established in May 1997, focusing on the research, production, and sales of medical imaging equipment [54] Group 28 - Company Qixia Construction announced a plan to reduce its shareholding by no more than 3% [55] - Company Qixia Construction was founded in December 1999, focusing on real estate development and management [56] Group 29 - Company Dasheng Intelligent signed a contract worth 11.5 million yuan for a high-efficiency machine room project [57] - Company Dasheng Intelligent was established in March 1995, focusing on AIoT intelligent management platforms [58] Group 30 - Company Huashi Technology announced an extension of the detention period for its actual controller [59] - Company Huashi Technology was founded in June 1998, focusing on information system integration and technical services [60] Group 31 - Company Tianzhihang announced plans to increase capital for its subsidiary [61] - Company Tianzhihang was established in October 2010, focusing on orthopedic surgical navigation robots [62] Group 32 - Company Pingzhi Information signed a procurement framework agreement with China Mobile for base station antennas [63] - Company Pingzhi Information was founded in November 2002, focusing on communication equipment and services [64] Group 33 - Company Mengke Pharmaceutical received acceptance for its new drug application for a new antibacterial drug [65] - Company Mengke Pharmaceutical was established in August 2012, focusing on small molecule drug research [66] Group 34 - Company Kede Education announced a change in its actual controller to a state-owned asset supervision committee [67] - Company Kede Education was founded in January 2003, focusing on education services [68] Group 35 - Company Jinlong Automobile elected a new chairman following the board meeting [69] - Company Jinlong Automobile was established in October 1996, focusing on the production and sales of buses [70] Group 36 - Company Jushen Co. received dividends totaling 95.7 million yuan from its subsidiaries [71] - Company Jushen Co. was founded in November 2011, focusing on logistics and warehousing services [72] Group 37 - Company Qingyun Technology announced plans for shareholders to reduce their holdings by up to 4.5% [73] - Company Qingyun Technology was established in April 2012, focusing on cloud computing products and services [74] Group 38 - Company Shengdexintai received a procurement notice from Dongfang Electric for a project worth 234 million yuan [75] - Company Shengdexintai was founded in October 2001, focusing on the production and sales of energy equipment [76] Group 39 - Company Juzhi Technology announced a plan for a director to reduce his holdings by up to 400,000 shares [77] - Company Juzhi Technology was established in November 2007, focusing on machine vision equipment [78] Group 40 - Company Sanrenxing announced plans for shareholders to reduce their holdings by up to 3% [79] - Company Sanrenxing was founded in August 2003, focusing on integrated marketing services [80] Group 41 - Company Transsion Holdings announced plans to increase capital for its subsidiary by 70 million yuan [81] - Company Transsion Holdings was established in August 2013, focusing on smart terminal design and sales [82] Group 42 - Company Jinling Pharmaceutical received approval for its raw material drug for iron deficiency anemia [83] - Company Jinling Pharmaceutical was founded in September 1998, focusing on drug manufacturing and healthcare services [84] Group 43 - Company Xiyu Tourism announced plans for shareholders to reduce their holdings by up to 3% [85] - Company Xiyu Tourism was established in January 2001, focusing on tourism and scenic area management [86]

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/5/30 | 2025/6/3 | 2025/6/3 | 一、 通过分配方案的股东大会届次和日期 证券代码：688578 证券简称：艾力斯 公告编号：2025-012 上海艾力斯医药科技股份有限公司 2024年年度权益分派实施公告 本次利润分配方案已经公司2025 年 5 月 14 日召开的2024年年度股东大会审议 通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本450,000,000股为基数，每股派发现 金红利0.40元（含税），共计派发现金红利180,000,000元（含税）。 是否涉及差异化分红送转：否 每股分配比例 每股现 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688578 证券简称：艾力斯 公告编号：2025-013 上海艾力斯医药科技股份有限公司自愿披露 关于枸橼酸戈来雷塞片新药上市申请获得批准的公告 得益于创新的药物共晶设计和稳定的构型,戈来雷塞有良好的安全性特征， ≥3 级治疗相关不良事件发生率更低，且具有良好的消化道安全性特征。戈来雷 塞是目前国内已获批的 KRAS G12C 抑制剂中，唯一实现每日单次口服给药的 KRAS G12C 抑制剂，患者服用更加方便。 二、对公司的影响 戈来雷塞非小细胞肺癌二线治疗适应症的上市申请完成审批，标志着戈来雷 塞商业化的正式开始，有利于丰富公司的商业化管线，提升公司的销售收入。公 司已组建了专业化的营销团队，将充分利用戈来雷塞的临床治疗优势，不断完善 产品的学术推广及产品营销策略，扩大戈来雷塞获批适应症的患者群体覆盖，提 升戈来雷塞的产品销售收入，并积极推动戈来雷塞非小细胞肺癌二线治疗适应症 尽快纳入国家医保目录，惠及更多肺癌患者。 上海艾力斯医药科技股份有限公司（以下简称"公 ...